Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca AbfiledCriticalAstrazeneca Ab
Priority to UY28499ApriorityCriticalpatent/UY28499A1/en
Publication of UY28499A1publicationCriticalpatent/UY28499A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Plural Heterocyclic Compounds
(AREA)
Abstract
Se describe una combinación que comprende N-(3-metoxi-5-metilpirazin-2-il)-2-(4-(1,3,4-oxadiazol-2-il)fenil)piridina-3-sulfonamida o una sal farmacéuticamente aceptable de la misma y un análogo de la LHRH y/o un bisfosfonato.A combination is described comprising N- (3-methoxy-5-methylpyrazin-2-yl) -2- (4- (1,3,4-oxadiazol-2-yl) phenyl) pyridine-3-sulfonamide or a salt pharmaceutically acceptable thereof and an analogue of LHRH and / or a bisphosphonate.
A PHARMACEUTICAL COMPOSITION THAT INCLUDES POLYMODIC FORMS OF 3- (4-AMINO-1-OXO-1.3 DYHIDRO-ISOINDOL-2-IL) -PIPERIDINA-2,6-DIONA FOR THE TREATMENT AND HANDLING OF CANCERES
NEW COMBINATION FROM REVERSIBLE ACTING PROTONE PUMP INHIBITORS AND USED IN THE THERAPY OF RESPIRATORY WAYS OF MEDICINAL SUBSTANCES FOR THE TREATMENT OF RESPIRATORY DISEASES